Schmid, P; Mordasini, A; Luginbühl, M; Regli, B; Kohler, H P; Zimmermann, H; Inderbitzin, D; Hirt, A; Lämmle, B; Alberio, L (2011). Low-dose recombinant factor VIIa for massive bleeding: A single centre observational cohort study with 73 patients. Swiss medical weekly, 141, w13213. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2011.13213
Full text not available from this repository.recombinant activated factor VII (rFVIIa) is used off-label for massive bleeding. There is no convincing evidence of the benefits of this practice and the minimal effective dose is unknown. The aim of the study was to evaluate our in-house guideline recommending a low dose of 60 μg/kg for off-label use of rFVIIa.